LTR

Inhibitory Selectivity

LTR Products

Catalog No. Information Product Use Citations Product Validations
S3998

(+)-α-Lipoic acid

R(+)-α-lipoic acid, a physiological form of thioctic acid, is a strong antioxidant that relieves diabetic neuropathic symptoms. It shows superior antioxidative effects to its racemate. α-Lipoic Acid is an antioxidant, which is an essential cofactor of mitochondrial enzyme complexes. α-Lipoic Acid inhibits NF-κB-dependent HIV-1 LTR activation.

S1633

Zafirlukast

Zafirlukast (ICI-204219) is an oral leukotriene receptor antagonist (LTRA), used to prevent asthma symptoms.

S4211

Montelukast Sodium

Montelukast (MK-0476) selectively antagonizes leukotriene D4 (LTD4) by binding to it so that block the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1. Montelukast improves macroautophagy but not the chaperone-mediated autophagy pathway. Precipitations may form after reconstitution,solution is best fresh-prepared.

S8126

MK571

MK571 (L660711) is a selective, orally active CysLT1 receptor(Cysteinyl leukotriene receptor) antagonist.

S5783

Montelukast

Montelukast is a leukotriene receptor antagonist used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies.

Catalog No. Information Product Use Citations Product Validations
S3998

(+)-α-Lipoic acid

R(+)-α-lipoic acid, a physiological form of thioctic acid, is a strong antioxidant that relieves diabetic neuropathic symptoms. It shows superior antioxidative effects to its racemate. α-Lipoic Acid is an antioxidant, which is an essential cofactor of mitochondrial enzyme complexes. α-Lipoic Acid inhibits NF-κB-dependent HIV-1 LTR activation.

Catalog No. Information Product Use Citations Product Validations
S1633

Zafirlukast

Zafirlukast (ICI-204219) is an oral leukotriene receptor antagonist (LTRA), used to prevent asthma symptoms.

S4211

Montelukast Sodium

Montelukast (MK-0476) selectively antagonizes leukotriene D4 (LTD4) by binding to it so that block the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1. Montelukast improves macroautophagy but not the chaperone-mediated autophagy pathway. Precipitations may form after reconstitution,solution is best fresh-prepared.

S8126

MK571

MK571 (L660711) is a selective, orally active CysLT1 receptor(Cysteinyl leukotriene receptor) antagonist.

S5783

Montelukast

Montelukast is a leukotriene receptor antagonist used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies.